Nasus Pharma Ltd. (NYSE: NSRX) received a No-Objection Letter from Health Canada to proceed with a Phase 2 clinical study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE